A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation

Arpit Dheeraj1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;2 School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

Chapla Agarwal1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Isabel R Schlaepfer3 Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

David Raben4 Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Rana Singh2 School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

Rajesh Agarwal1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Gagan Deep5 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA;6 Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA;7 Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USACorrespondence[email protected]

show all

A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation

Citations (1)

Read on this site (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date